Literature DB >> 32755614

Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.

Chunzhan Wang1, Shengguang Ding2, Baisheng Sun3, Liang Shen4, Ling Xiao5, Zhihai Han6, Haitao Huang7.   

Abstract

The efficacy of molecular targeting agents is dependent on the metabolism or nuclear receptor-mediated clearance of chemotherapy resistance-related factors such as cytochrome P450 (CYP) or ATP binding cassette subfamily B member 1 (ABCB1). In this study, we revealed the roles of the microRNA-4271/CAR (constitutive androstane receptor) axis in the regulation of the resistance to molecular anticancer targeting agents in non-small cell lung cancer (NSCLC) cells including two main categories of NSCLC: lung adenocarcinoma (AC) and large cell lung cancer (LCC). The expression of miR-4271 was negatively correlated with CAR expression in NSCLC tissues. MiR-4271 targeted CAR and inhibited the activation of the CAR signaling pathway. Overexpression of CAR in NSCLC enhanced the resistance of NSCLC cells to molecular targeting agents and miR-4271-infected NSCLC cells enhanced their sensitivity to molecular targeting agents such as Gefitinib. The mechanism-data showed that overexpression of miR-4271 decelerated the mechanism or the clearance of molecular targeting agents by targeting the 3'UTR (3' un-translation region). These results suggest that miR-4271 may contribute to the development of more effective strategies for the treatment of advanced NSCLC.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Constitutive androstane receptor; Molecular targeting agents; Non-Small cell lung cancer; microRNA-4271

Year:  2020        PMID: 32755614     DOI: 10.1016/j.phrs.2020.105110

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  12 in total

1.  Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA.

Authors:  Qijie Ran; Dehong Xu; Qi Wang; Dongsheng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs.

Authors:  De-Bin Ma; Xing-Yu Liu; Hui Jia; Yingshi Zhang; Qiyu Jiang; Huiwei Sun; Xiaojuan Li; Fang Sun; Yantao Chai; Fan Feng; Lei Liu
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

3.  Serum Exosomes MicroRNAs Are Novel Non-Invasive Biomarkers of Intrahepatic Cholestasis of Pregnancy.

Authors:  Ruirui Dong; Ningzhen Ye; Jing Wang; Shaojie Zhao; Tiejun Wang; Gaoying Wang; Xinrui Shi; Jing Cheng; Yan Zhang; Tingting Yao; Minjian Chen; Ting Zhang; Liang Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

4.  The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents.

Authors:  Li-Jun Shen; Hui-Wei Sun; Yan-Yao Chai; Qi-Yu Jiang; Jian Zhang; Wen-Ming Li; Shao-Jie Xin
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

5.  Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation.

Authors:  Xiao-Zheng Zou; Jun-Feng Hao; Xiu-Hua Zhou
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

6.  ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM.

Authors:  Hua Ren; Zhi-Cheng Wei; Yan-Xia Sun; Chun-Yan Qiu; Wen-Jue Zhang; Wei Zhang; Tao Liu; Xu Che
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

7.  A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells.

Authors:  Yuan-Yuan Liu; Cheng-Zhi Ding; Jia-Ling Chen; Zheng-Shuai Wang; Bin Yang; Xiao-Ming Wu
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

8.  TPX2 Enhanced the Activation of the HGF/ETS-1 Pathway and Increased the Invasion of Endocrine-Independent Prostate Carcinoma Cells.

Authors:  Qinghong Zhou; Mingsheng Liu; Tao Shao; Pingbo Xie; Shaojie Zhu; Wei Wang; Qiong Miao; Jiaxi Peng; Peng Zhang
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 5.738

9.  FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis.

Authors:  Hua Yang; Lili Ren; Yanan Wang; Xuebing Bi; Xiaoli Li; Ming Wen; Qian Zhang; Yang Yang; Youchao Jia; Yumiao Li; Aimin Zang; Yaning Wei; Guanghai Dai
Journal:  Cell Death Dis       Date:  2020-10-13       Impact factor: 8.469

10.  MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor.

Authors:  Qiyu Jiang; Yan Ma; Jingjing Han; Jingdong Chu; Xuemei Ma; Lijun Shen; Bo Liu; Bo-An Li; Jun Hou; Qian Bi
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.